Sera Prognostics Company
Sera Prognostics develops blood tests that are predictive of preterm birth, preeclampsia, and other pregnancy complications.
Investors
.png)
Total Funding:
$250,324,197
Headquarters:
Salt Lake City, Utah, United States
Funding Status:
IPO
Employee Number:
51-100
Estimated Revenue:
$10M to $50M
Investment Stage:
N/A
Last Funding Type:
Series E
Number Of Exists:
Series D
Technology:
Pregnancy biomarkers
Investor Type:
Company
Last Funding Date:
2021-04-28
Investors Number:
13
Founded Date:
01-01-2008
Industry:
Pregnancy & Nursing